CAMP4 Therapeutics Corporation (NASDAQ:CAMP – Get Free Report) Director Andrew Schwab sold 400,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the completion of the transaction, the director directly owned 2,033,270 shares of the company’s stock, valued at approximately $8,214,410.80. The trade was a 16.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
CAMP4 Therapeutics Stock Down 4.6%
CAMP4 Therapeutics stock traded down $0.19 during mid-day trading on Monday, reaching $3.96. 190,269 shares of the company’s stock were exchanged, compared to its average volume of 187,803. The company has a fifty day moving average of $4.13 and a 200-day moving average of $4.36. The company has a market cap of $248.49 million, a P/E ratio of -1.71 and a beta of 0.22. CAMP4 Therapeutics Corporation has a twelve month low of $1.41 and a twelve month high of $7.75.
CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. The company had revenue of $1.78 million during the quarter. Equities research analysts expect that CAMP4 Therapeutics Corporation will post -0.57 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Analysis on CAMP
Institutional Investors Weigh In On CAMP4 Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jupiter Topco LLC acquired a new position in CAMP4 Therapeutics in the second quarter valued at $27,581,000. Janus Henderson Group PLC increased its position in shares of CAMP4 Therapeutics by 35.9% during the fourth quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock worth $38,807,000 after purchasing an additional 1,666,666 shares in the last quarter. 5AM Venture Management LLC purchased a new stake in shares of CAMP4 Therapeutics in the 2nd quarter valued at about $25,647,928. Vivo Capital LLC boosted its position in shares of CAMP4 Therapeutics by 8.3% in the 4th quarter. Vivo Capital LLC now owns 4,246,568 shares of the Wireless communications provider’s stock valued at $26,031,000 after purchasing an additional 325,000 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of CAMP4 Therapeutics in the 4th quarter valued at about $14,938,000.
CAMP4 Therapeutics Company Profile
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.
Featured Stories
- Five stocks we like better than CAMP4 Therapeutics
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
